Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel Free MRAI Stock Alerts

Marpai (MRAI) Competitors

Marpai logo
$0.27 +0.02 (+10.04%)
As of 01:01 PM Eastern
Compare

MRAI vs. PIII, CCM, BMGL, ACON, and ADVB

Should you be buying Marpai stock or one of its competitors? The main competitors of Marpai include P3 Health Partners (PIII), Concord Medical Services (CCM), Basel Medical Group (BMGL), Aclarion (ACON), and Advanced Biomed (ADVB). These companies are all part of the "healthcare" industry.

How does Marpai compare to P3 Health Partners?

P3 Health Partners (NASDAQ:PIII) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Marpai has lower revenue, but higher earnings than P3 Health Partners. Marpai is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
P3 Health Partners$1.46B0.01-$147.95M-$45.20N/A
Marpai$34.87M0.20-$28.75M-$0.95N/A

In the previous week, Marpai had 1 more articles in the media than P3 Health Partners. MarketBeat recorded 1 mentions for Marpai and 0 mentions for P3 Health Partners. Marpai's average media sentiment score of 1.08 beat P3 Health Partners' score of 0.00 indicating that Marpai is being referred to more favorably in the news media.

Company Overall Sentiment
P3 Health Partners Neutral
Marpai Positive

7.8% of P3 Health Partners shares are owned by institutional investors. Comparatively, 49.8% of Marpai shares are owned by institutional investors. 17.8% of P3 Health Partners shares are owned by company insiders. Comparatively, 46.1% of Marpai shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

P3 Health Partners has a net margin of -10.14% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat P3 Health Partners' return on equity.

Company Net Margins Return on Equity Return on Assets
P3 Health Partners-10.14% -302.33% -20.72%
Marpai -85.70%N/A -100.23%

P3 Health Partners currently has a consensus price target of $3.50, suggesting a potential upside of 21.11%. Given P3 Health Partners' stronger consensus rating and higher probable upside, equities research analysts clearly believe P3 Health Partners is more favorable than Marpai.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
P3 Health Partners
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Marpai
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

P3 Health Partners has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Marpai has a beta of 4.39, indicating that its stock price is 339% more volatile than the S&P 500.

Summary

Marpai beats P3 Health Partners on 9 of the 16 factors compared between the two stocks.

How does Marpai compare to Concord Medical Services?

Concord Medical Services (NYSE:CCM) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Concord Medical Services
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Marpai
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Concord Medical Services has higher revenue and earnings than Marpai.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Concord Medical Services$460.51M0.04-$13.27MN/AN/A
Marpai$34.87M0.20-$28.75M-$0.95N/A

In the previous week, Concord Medical Services had 8 more articles in the media than Marpai. MarketBeat recorded 9 mentions for Concord Medical Services and 1 mentions for Marpai. Marpai's average media sentiment score of 1.08 beat Concord Medical Services' score of 0.15 indicating that Marpai is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Concord Medical Services
0 Very Positive mention(s)
0 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Marpai
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

49.8% of Marpai shares are owned by institutional investors. 46.5% of Concord Medical Services shares are owned by company insiders. Comparatively, 46.1% of Marpai shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Concord Medical Services has a beta of -1.09, indicating that its stock price is 209% less volatile than the S&P 500. Comparatively, Marpai has a beta of 4.39, indicating that its stock price is 339% more volatile than the S&P 500.

Concord Medical Services has a net margin of 0.00% compared to Marpai's net margin of -85.70%.

Company Net Margins Return on Equity Return on Assets
Concord Medical ServicesN/A N/A N/A
Marpai -85.70%N/A -100.23%

Summary

Concord Medical Services beats Marpai on 7 of the 11 factors compared between the two stocks.

How does Marpai compare to Basel Medical Group?

Marpai (NASDAQ:MRAI) and Basel Medical Group (NASDAQ:BMGL) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marpai
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Basel Medical Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Basel Medical Group has lower revenue, but higher earnings than Marpai.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marpai$34.87M0.20-$28.75M-$0.95N/A
Basel Medical Group$8.90M1.28-$9.50MN/AN/A

In the previous week, Marpai had 1 more articles in the media than Basel Medical Group. MarketBeat recorded 1 mentions for Marpai and 0 mentions for Basel Medical Group. Marpai's average media sentiment score of 1.08 beat Basel Medical Group's score of 0.00 indicating that Marpai is being referred to more favorably in the media.

Company Overall Sentiment
Marpai Positive
Basel Medical Group Neutral

49.8% of Marpai shares are owned by institutional investors. 46.1% of Marpai shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Marpai has a beta of 4.39, indicating that its share price is 339% more volatile than the S&P 500. Comparatively, Basel Medical Group has a beta of 0.07, indicating that its share price is 93% less volatile than the S&P 500.

Basel Medical Group has a net margin of 0.00% compared to Marpai's net margin of -85.70%.

Company Net Margins Return on Equity Return on Assets
Marpai-85.70% N/A -100.23%
Basel Medical Group N/A N/A N/A

Summary

Marpai beats Basel Medical Group on 6 of the 11 factors compared between the two stocks.

How does Marpai compare to Aclarion?

Marpai (NASDAQ:MRAI) and Aclarion (NASDAQ:ACON) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

49.8% of Marpai shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 46.1% of Marpai shares are owned by company insiders. Comparatively, 0.8% of Aclarion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Marpai has a net margin of -85.70% compared to Aclarion's net margin of -9,517.11%. Marpai's return on equity of 0.00% beat Aclarion's return on equity.

Company Net Margins Return on Equity Return on Assets
Marpai-85.70% N/A -100.23%
Aclarion -9,517.11%-52.31%-49.79%

Aclarion has lower revenue, but higher earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marpai$34.87M0.20-$28.75M-$0.95N/A
Aclarion$80K98.40-$7.23M-$17.01N/A

In the previous week, Aclarion had 1 more articles in the media than Marpai. MarketBeat recorded 2 mentions for Aclarion and 1 mentions for Marpai. Marpai's average media sentiment score of 1.08 beat Aclarion's score of 0.00 indicating that Marpai is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Marpai
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aclarion
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marpai
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aclarion
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Marpai has a beta of 4.39, indicating that its share price is 339% more volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500.

Summary

Marpai beats Aclarion on 9 of the 14 factors compared between the two stocks.

How does Marpai compare to Advanced Biomed?

Marpai (NASDAQ:MRAI) and Advanced Biomed (NASDAQ:ADVB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

Marpai has a beta of 4.39, indicating that its stock price is 339% more volatile than the S&P 500. Comparatively, Advanced Biomed has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.

In the previous week, Marpai and Marpai both had 1 articles in the media. Advanced Biomed's average media sentiment score of 1.29 beat Marpai's score of 1.08 indicating that Advanced Biomed is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Marpai
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Advanced Biomed
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

49.8% of Marpai shares are held by institutional investors. 46.1% of Marpai shares are held by insiders. Comparatively, 34.4% of Advanced Biomed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marpai
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Advanced Biomed
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Advanced Biomed has lower revenue, but higher earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marpai$34.87M0.20-$28.75M-$0.95N/A
Advanced BiomedN/AN/A-$3.26M$3.801.81

Advanced Biomed has a net margin of 0.00% compared to Marpai's net margin of -85.70%. Advanced Biomed's return on equity of 92.11% beat Marpai's return on equity.

Company Net Margins Return on Equity Return on Assets
Marpai-85.70% N/A -100.23%
Advanced Biomed N/A 92.11%58.03%

Summary

Advanced Biomed beats Marpai on 8 of the 12 factors compared between the two stocks.

Get Marpai News Delivered to You Automatically

Sign up to receive the latest news and ratings for MRAI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MRAI vs. The Competition

Export
MetricMarpaihealth & allied services, not elsewhere classified IndustryBusiness SectorNASDAQ Exchange
Market Cap$6.86M$79.31M$6.40B$11.87B
Dividend YieldN/AN/A3.03%5.21%
P/E Ratio-0.100.7425.8528.48
Price / Sales0.200.14430.6960.89
Price / CashN/A4.1922.9236.52
Price / Book-0.160.156.086.67
Net Income-$28.75M$25.15M$200.90M$332.64M
7 Day Performance4.88%1.66%1.27%2.01%
1 Month Performance-17.97%-12.31%7.46%9.19%
1 Year Performance-74.22%-31.34%56.26%39.59%

Marpai Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MRAI
Marpai
N/A$0.27
+10.0%		N/AN/A$6.86M$34.87MN/A150
PIII
P3 Health Partners
1.7363 of 5 stars		$2.80
-3.1%		$3.50
+25.0%		N/A$20.19M$1.46BN/A500
CCM
Concord Medical Services
0.2633 of 5 stars		$3.82
+0.4%		N/AN/A$16.60M$365.76MN/A970
BMGL
Basel Medical Group
0.2139 of 5 stars		$0.56
-10.1%		N/AN/A$10.52M$8.90MN/A36
ACON
Aclarion
0.1327 of 5 stars		$3.26
-3.3%		N/AN/A$7.43M$80KN/A7

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MRAI) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel